Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological Malignancies

Gelijkaardige items

• Recent advances in the development of Aurora kinases inhibitors in hematological malignancies
  door: Choudary, Iqra, et al.
  Gepubliceerd in: (2015)
• Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT and FLT3 in hematologic malignancies: Mutant KIT and FLT3 response to Tyrosine Kinase Inhibitors
  door: Weisberg, Ellen, et al.
  Gepubliceerd in: (2019)
• Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy
  door: Weisberg, Ellen, et al.
  Gepubliceerd in: (2017)
• Effects of the multi‐kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia
  door: Weisberg, Ellen, et al.
  Gepubliceerd in: (2020)
• A Systematic Review of Recently Reported Marine Derived Natural Product Kinase Inhibitors
  door: Li, Te, et al.
  Gepubliceerd in: (2019)